● Medix Biochemica收購了頂級(jí)免疫檢測(cè)解決方案的領(lǐng)先供應(yīng)商CANDOR Bioscience,該公司位于德國旺根。
Medix Biochemica acquires CANDOR Bioscience, a leading provider of premium immunoassay solutions, based in Wangen, Germany.
● 本次收購進(jìn)一步加強(qiáng)了Medix Biochemica體外診斷關(guān)鍵原料產(chǎn)品線,并提升了其為全球IVD產(chǎn)品開發(fā)者提供支持的能力。
The acquisition strengthens Medix Biochemica’s portfolio in critical raw materials for in vitro diagnostics (IVD) and enhances its capability to support immunoassay developers across the world.
● Medix Biochemica的愿景,是成為體外診斷行業(yè)的首選原料合作伙伴。
Medix Biochemica’s vision is to be the first-choice raw material partner for the IVD industry.
—— 關(guān)于收購 ——
2025 年 1 月 22 日,芬蘭埃斯波 - 體外診斷行業(yè)關(guān)鍵原料全球領(lǐng)先供應(yīng)商Medix Biochemica宣布收購CANDOR Bioscience GmbH。CANDOR Bioscience位于德國,是優(yōu)質(zhì)免疫檢測(cè)解決方案的開發(fā)商和制造商。此次收購既強(qiáng)化了Medix Biochemica高品質(zhì)體外診斷關(guān)鍵原料產(chǎn)品線,又在試劑開發(fā)方面提升了其為IVD試劑生產(chǎn)商提供支持的能力。交易完成后,CANDOR Bioscience高質(zhì)量的運(yùn)營將繼續(xù)保留在德國阿爾高地區(qū)旺根。
22 January 2025, Espoo, Finland – Medix Biochemica, a global leader in the supply of critical raw materials for the in vitro diagnostics (IVD) industry, announced the acquisition of CANDOR Bioscience GmbH, a Germany-based developer and manufacturer of premium immunoassay solutions. The acquisition both strengthens Medix Biochemica’s range of high-quality raw materials to the worldwide IVD industry and enhances its capabilities to support test manufacturers in immunoassay development. Following the transaction, CANDOR Bioscience’s high-quality operations will remain in Wangen im Allgäu, Germany.
—— 關(guān)于CANDOR Bioscience ——
CANDOR Bioscience由Tobias Polifke博士和Peter Rauch博士創(chuàng)立于2004年,是一家德國企業(yè),提供種類齊全的優(yōu)質(zhì)免疫分析解決方案;產(chǎn)品包括人抗鼠抗體 (HAMA)、干擾阻斷劑、表面阻斷劑、穩(wěn)定劑和緩沖液。借助CANDOR Bioscience的解決方案,免疫檢測(cè)試劑生產(chǎn)商可以提高檢測(cè)結(jié)果的可靠性,簡(jiǎn)化實(shí)驗(yàn)設(shè)計(jì)、縮短開發(fā)流程。
CANDOR Bioscience, founded in 2004 by Dr Tobias Polifke and Dr Peter Rauch, is a German provider of a comprehensive selection of premium solutions for immunoassays, including HAMA and interference blockers, surface blockers, stabilizers and buffer solutions. By using CANDOR Bioscience’s solutions, immunoassay manufacturers can improve reliability of test results, simplify assay designs and reduce process times.
—— 共同愿景 ——
“我們很高興CANDOR加入Medix Biochemica大家庭!通過與CANDOR的合作、增加免疫檢測(cè)開發(fā)方面的互補(bǔ)專長、憑借一流的優(yōu)質(zhì)阻斷劑和穩(wěn)定劑產(chǎn)品線拓寬我們關(guān)鍵體外診斷 (IVD) 原料的供應(yīng)范圍,將進(jìn)一步強(qiáng)化Medix Biochemica服務(wù)客戶的能力。我們將攜手繼續(xù)提供超優(yōu)質(zhì)的原料、推動(dòng)診斷技術(shù)創(chuàng)新,并且我們期待與CANDOR團(tuán)隊(duì)展開成功合作。” Medix Biochemica首席執(zhí)行官Steve Ferguson表示。
“We are delighted to welcome CANDOR into the Medix Biochemica family. The partnership with CANDOR strengthens Medix Biochemica’s ability to support our customer base by adding complementary expertise in immunoassay development and broadening our offering of critical IVD raw materials with a leading portfolio of premium blockers and stabilizers. Together, we will continue to provide the highest quality raw materials that enable diagnostic innovation, and we look forward to a successful collaboration with the CANDOR team,” says Steve Ferguson, CEO of Medix Biochemica.
CANDOR Bioscience的聯(lián)合創(chuàng)始人兼董事總經(jīng)理Tobias Polifke博士和Peter Rauch博士對(duì)此次合作倍感興奮:“與Medix Biochemica攜手,對(duì)CANDOR而言是一個(gè)激動(dòng)人心的里程碑。我們?yōu)樽约涸诿庖邫z測(cè)開發(fā)提供差異化、高性能解決方案方面的傳統(tǒng)而感到自豪,并且我們與Medix Biochemica一樣,致力于質(zhì)量與創(chuàng)新。通過整合我們的能力與產(chǎn)品,我們將更有能力滿足客戶不斷變化的需求。Medix Biochemica的產(chǎn)品,包括抗體和質(zhì)控原料,與我們的解決方案完美互補(bǔ),提升了我們?yōu)轶w外診斷 (IVD) 行業(yè)合作伙伴創(chuàng)造的價(jià)值。”
Dr Tobias Polifke and Dr Peter Rauch, co-founders and Managing Directors of CANDOR Bioscience, are excited about the partnership: “Joining forces with Medix Biochemica is an exciting milestone for CANDOR. We are proud of our legacy in providing differentiated, high-performance solutions for immunoassay development, and we share Medix Biochemica’s commitment to quality and innovation. By combining our capabilities and offerings, we will be better positioned to support the evolving needs of our customers. Medix Biochemica’s products, including antibodies and quality control materials, perfectly complement our solutions, enhancing the value we offer to partners in the IVD industry”.
如需更多信息,請(qǐng)與聯(lián)系我們:
Medix Biochemica 中國商務(wù)團(tuán)隊(duì)
Commercial Team of Medix Biochemica China
電話: +86 21 6811 9180, 6811 9181, 6811 9105
郵箱: medixchina@medixbiochemica.com
網(wǎng)站: onb2b.cn
· 關(guān)于 Medix Biochemica
Medix Biochemica是體外診斷 (IVD) 行業(yè)關(guān)鍵原料全球領(lǐng)先獨(dú)立供應(yīng)商。公司面向全球 IVD 企業(yè)研發(fā)、生產(chǎn)并供應(yīng)高質(zhì)量抗體、抗原及其他關(guān)鍵 IVD 原料,為數(shù)十億患者提供準(zhǔn)確的 IVD 檢測(cè)賦能。公司的主要股東DevCo Partners,是一家著眼長遠(yuǎn)的積極控股方與發(fā)展合作伙伴,致力于在特定細(xì)分市場(chǎng)打造世界領(lǐng)先企業(yè)。
· 關(guān)于 CANDOR Bioscience
CANDOR Bioscience GmbH專注于開發(fā)和生產(chǎn)免疫檢測(cè)用高質(zhì)量解決方案。其產(chǎn)品包括穩(wěn)定劑和阻斷劑,在全球范圍內(nèi)被用于提高免疫檢測(cè)試劑的準(zhǔn)確性和可靠性。CANDOR Bioscience成立于 2004 年,因提供性能穩(wěn)定的優(yōu)質(zhì)產(chǎn)品而享有盛譽(yù)。